We are happy to announce the immediate availability of Target Discovery, an AI- powered platform that speeds the process of discovering new safe & efficient drug candidates. Target Discovery combines knowledge from public and proprietary data, AI-derived data from scientific publications, patents and clinical trials. It also features powerful analytics for target identification and selection, while empowering medical or scientific experts without technical skills to leverage.
Developing new treatments requires a complex understanding of disease mechanisms and the ability to identify the relationships between molecular and genetic factors in the context of a specific disease – said Todor Primov, Head of Life Sciences Product and Solutions at Ontotext. – This knowledge, however, is scattered across multiple disparate sources representing different modalities. Therefore, building a holistic view for a specific disease context is a challenge. We believe that knowledge graph technology significantly lowers the cost and shortens the time for semantic data integration. It also brings in a completely new level of more profound insights on top of highly connected data and provides highly normalized quality data for supporting AI analysis
Benefits of Target Discovery include:
Target Discovery stays up-to-date with the newest discoveries by automatically extracting knowledge from more than 80 million documents, including patents and clinical trials. It’s easy to discover new insights, analyze data visually or with powerful algorithms and leverage a vast network of knowledge for improved decision-making.
Discovering the next breakthrough drug candidate can be a daunting task, involving sifting through vast amounts of biomedical information scattered across different databases and research publications. Target Discovery combines all required data, whether public or proprietary, AI-derived or structured, in one place and makes it easily discoverable and analytics-ready. All information is updated regularly and features a selection of the most useful, newest industry leading publishers such as AlphaFold, Open Targets, EMBL.
One can quickly gain an overview of a disease or target with customizable visual analytics and dashboards over any type of data and source. These are fully configurable and easy to use by expert users.
Hidden relationships can be easily uncovered in a network of over 5 billion facts with advanced graph algorithms. One can build new, sound biological hypotheses with high confidence in minutes.
Improving confidence in critical decision-making processes by gaining more transparency over the information and analytics. With Target Discovery, fact traceability is better and evidence is presented on different levels, so that users trust their data, and not rely on potentially faulty ‘gut’ decisions.
For more information, contact Doug Kimball, Chief Marketing Officer at Ontotext